Histiocytosis Treatments

Find Histiocytosis Treatments

Brand Name

Zelboraf

Generic Name

Vemurafenib

View Brand Information

FDA approval date: August 17, 2011

Classification: Kinase Inhibitor

Form: Tablet

What is Zelboraf (Vemurafenib)?

ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Randomized, Multi-Center, Phase II Study of Vemurafenib Plus Obinutuzumab vs. Cladribine Plus Rituximab in Patients With Previously Untreated Hairy Cell Leukemia (HCL)

Enrollment Status: Recruiting

Publish Date: April 15, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of c...

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

Who is this study for: Patients with operable Stage IIA, IIB, IIIA, and select IIIB resectable and untreated non-small cell lung cancer tumors with selected molecular alterations

Enrollment Status: Recruiting

Publish Date: April 03, 2026

Intervention Type: Drug, Procedure

Study Drugs: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Chemotherapy, Pralsetinib

Study Phase: Phase 2

Summary: This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Who is this study for: Patients with Lymphoma, Myeloma, Tumors

Enrollment Status: Recruiting

Publish Date: April 02, 2026

Intervention Type: Drug

Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)

Study Phase: Phase 2

Summary: The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a pati...

View All Clinical Trials

Related Latest Advances

Inhibitory effect of vemurafenib combined with panobinostat on human anaplastic thyroid cancer cells.

Journal: Pakistan journal of pharmaceutical sciences

Published: March 25, 2026

Development and Preliminary Evaluations of a Novel 18F-Labeled Tracer for Detection of BRAFV600E Mutant Status in Animal Models of Melanoma.

Journal: Molecular pharmaceutics

Published: March 13, 2026

Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].

Journal: The Journal of investigative dermatology

Published: March 13, 2026

View All Latest Advances